14 results about "Plasmacytoid dendritic cell" patented technology

The present invention relates to a biomarker for diagnosing pediatric atopic dermatitis and use thereof. As result of comparing immune phenotypes of a healthy control group with those of pediatric atopic dermatitis patients, it has been identified that Th1, Th2, Th17 and Th22 cells or expression of STAT1, CD6 and ALCAM genes are increased or decreased. In addition, in the present invention, it has been identified that the frequencies of monocytes, plasmacytoid dendritic cells, CD4 central memory T cells, and CD4 effector memory T cells are related to the severity of pediatric atopic dermatitis. Therefore, the present invention can ensure an efficient treatment strategy for pediatric atopic dermatitis by accurately diagnosing pediatric atopic dermatitis and the severity thereof.

The present invention provides a composition for use in applications such as activating plasmacytoid dendritic cells (pDCs), the composition containing Lactobacillus sakei, MG-LAB279 strain (accession number: NITE BP-03645), and / or a bacterial cell component thereof as an active ingredient.

Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.

The present invention discloses an anti-BDCA2 antibody and its antigen-binding fragment, a polynucleotide encoding the antibody and its antigen-binding fragment, and a pharmaceutical composition comprising the antibody and its antigen-binding fragment. Furthermore, the use of the anti-BDCA2 antibody and its antigen-binding fragment described in the present invention in the treatment of plasmacytoid dendritic cell (pDC) or type I interferon (type I IFN)-associated immune diseases is also disclosed.

To provide a composition for activating plasmacytoid dentritic cells, which does not require expensive culture equipment for its active ingredient (Tetragenococcus lactic acid bacteria), hardly requires labor and cost in production, is a safe food material, and further activates plasmacytoid dentritic cells.SOLUTION: The composition for activating the plasmacytoid dentritic cells contains at least one kind selected from Tetragenococcus lactic acid bacteria activating the plasmacytoid dentritic cells and cultures of the lactic acid bacteria.SELECTED DRAWING: None

To provide a composition for immunostimulation.SOLUTION: A composition for immunostimulation comprising, as an active ingredient, a bacterium phagocytosed by plasmacytoid dentritic cells (pDCs) to a predetermined degree or more and / or a bacterium binding to BDCA2.SELECTED DRAWING: None

Disclosed herein are compositions comprising a hydrogel scaffold, methods of generating a hydrogel scaffold, and systems for and methods of using the hydrogel scaffold to produce biologically active molecules.

Provided herein are IL-10 variant sequences. In some embodiments, the IL-10 variants are immunosilent, and / or are capable of suppressing monocyte, macrophage, or pDC activity. Also disclosed herein are vaccines comprising the IL-10 variants, and methods of treatment for diseases and disorders that correspond with activating adaptive immunity.

The diagnostic markers that provide novel diagnostic criteria to blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been searched, and the presence of immunoblastoid cytomorphology, 8q24 rearrangement, and MYC expression were established as novel markers for subtyping BPDCN. It has been further found that the inhibitors which directly or indirectly inhibit the expression, functions, or signaling pathways of MYC, such as BET bromodomain-selective inhibitors or aurora kinase inhibitors, are effective in MYC-positive BPDCN, and HDAC inhibitors or BCL2 family protein inhibitors are effective as therapeutic drugs for BPDCN.

The present invention addresses the problem of providing a bacterium belonging to Lactobacillus helveticus, which has an excellent IFN production-inducing effect. The present invention relates to a bacterium classified as Lactobacillus helveticus, which is capable of activating plasma-like dendritic cells (pDC) and / or myeloid dendritic cells (mDC) and inducing the production of type I IFN, and which induces the production of type I IFN at a level of 1.5 times or more as compared to that of Lactobacillus helveticus SBT2171 (accession number: Ferm BP-5445), and more particularly, to a bacterium classified as Lactobacillus helveticus, which is capable of activating plasma-like dendritic cells (pDC) and / or myeloid dendritic cells (mDC) and inducing the production of type I IFN at a level of 1.5 times or more than that of Lactobacillus helveticus SBT2171 (accession number: Ferm BP-5445).

The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated / synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.

The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated / synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.

The present invention relates, in part, to agents, chimeric proteins and chimeric protein complexes that bind a plasmacytoid dendritic cell (pDC), e.g. Clec4C and their use as diagnostic and therapeutic agents. The present Invention further relates to pharmaceutical compositions comprising the pDC, e.g. Clec4C, binding agents, chimeric proteins, or chimeric protein complexes and their use in the treatment of various diseases, including autoimmune diseases.

The application provides a biomarker combination for in vitro diagnosis of membranous nephropathy, comprising non-classical monocytes, CD4+ T cells, effector CD4+ T cells, type 2 helper T cells, double negative T cells, central memory CD4+ T cells, plasmacytoid dendritic cells, antibody-secreting cells, total T cells, unswitched memory B cells, classical monocytes and natural killer cells. The application also provides a method for constructing a membranous nephropathy diagnosis model, comprising a step of screening characteristic biomarkers and a step of constructing and evaluating the performance of a diagnosis model. The application screens the optimal marker combination from high-dimensional flow cytometry data by applying a random forest recursive feature elimination algorithm, and constructs a random forest diagnosis model. The application shows excellent performance in distinguishing membranous nephropathy patients from healthy controls, and demonstrates high accuracy in independent verification including a difficult-to-diagnose subgroup of PLA2R antibody-negative patients.